News

Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance.

LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver.

Resonance Health Ltd has today signed a Patient Access to FerriSmart® Letter of Agreement with the World Health Organization related Cyprus based Thalassaemia International Federation (TIF).

Resonance Health Ltd has today signed a Patient Access to FerriSmart® Letter of Agreement with the World Health Organization related Cyprus based Thalassaemia International Federation (TIF).

Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance.

LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver.

Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance. LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, …

Introducing LiverSmart: A New AI Medical Device Read More »

Resonance Health attended the EASL Digital NAFLD Summit 2021 on 16 – 17 September and participated with insights into developments in artificial intelligence-based approaches to NAFLD management using HepaFat-AI.

Resonance Health attended the EASL Digital NAFLD Summit 2021 on 16 – 17 September and participated with insights into developments in artificial intelligence-based approaches to NAFLD management using HepaFat-AI.

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager – Global Sales & Marketing.

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager – Global Sales & Marketing.

Burjeel Medical City opens Thalassemia Center to help children with Thalassemia

VPS Healthcare’s premium medical facility, Burjeel Medical City at Mohammed Bin Zayed City, Abu Dhabi, has opened a Thalassemia Center to offer exclusive treatment for children diagnosed with the illness.